Omadacycline is a broad-spectrum aminomethylcycline tetracycline (81.1%) was reduced. Omadacycline was also highly active against E. faecium (99.7%) and Enterococcus faecalis (99.3%), and enterococci from patients in European medical centres participated in the SENTRY surveillance mechanisms. The

Omadacycline and Comparator Antimicrobial Activity against Gram-Positive and Gram-Negative Pathogens

### MATERIALS AND METHODS

- **In vitro Testing**: Susceptibility testing was performed according to CLSI (M07-A10, 2015). The following antibacterial agents were tested: amoxicillin, ampicillin, clindamycin, cefoxitin, gentamicin, imipenem, linezolid, meropenem, oxacillin, penicillin, polymyxin B, and vancomycin.
- **In vitro Study**: A total of 6,289 isolates were included from all regions and species groups. The organisms included coagulase-negative staphylococci (CoNS), beta-haemolytic streptococci, viridans group streptococci, enterococci, and staphylococci. The organisms included in the study were:
  - **S. aureus**: Including 80 MRSA strains and 20 MSSA strains.
  - **S. epidermidis**: Including 247 CoNS strains.
  - **S. pyogenes**: Including 223 beta-haemolytic streptococci.
  - **S. gordonii**: Including 221 viridans group streptococci.
  - **S. mutans**: Including 349 enterococci.

### RESULTS

- **Omadacycline vs Comparator**: Omadacycline was highly active against S. pneumoniae (MIC90: 0.06 mg/L), E. faecalis (MIC90: 0.06 mg/L), and all other gram-positive pathogens tested, including S. pyogenes and enterococci.
- **Comparative Activity**: Omadacycline was highly active against all tested gram-positive pathogens, with MIC90 values ranging from 0.06 to 0.12 mg/L.

### CONCLUSIONS

- Omadacycline is a broad-spectrum antibiotic that is highly active against a wide range of gram-positive pathogens, including S. aureus, S. pneumoniae, and enterococci.
- The results support the continued development and clinical use of omadacycline in infections where resistant isolates of staphylococci, streptococci, and enterococci are prevalent.\n
### ACKNOWLEDGEMENTS

This study and abstract presentation were funded by a research grant from Paratek Pharmaceuticals, Inc.

### REFERENCES


---

### CONCLUSIONS

- Omadacycline is a broad-spectrum antibiotic that is highly active against all tested gram-positive pathogens, including S. aureus, S. pneumoniae, and enterococci.
- The results support the continued development and clinical use of omadacycline in infections where resistant isolates of staphylococci, streptococci, and enterococci are prevalent.

---

### ACKNOWLEDGEMENTS

This study and abstract presentation were funded by a research grant from Paratek Pharmaceuticals, Inc.

### REFERENCES